SCHEMBL2197429

SCHEMBL2197429

COc1ccc(C(=O)NCCF)cc1C(=O)c1ccc(Nc2c(F)cccc2F)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 1/20 0.44
MAPK12 P53778 1/20 0.44
MAPK11 Q15759 1/20 0.44
MAPK14 Q16539 1/20 0.44
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 1/20 0.43
PDE4D Q08499 4/20 0.42
HDAC6 Q9UBN7 1/20 0.41
MCHR1 Q99705 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
HDAC8 Q9BY41 2/20 0.39
ROCK2 O75116 1/20 0.39
APLNR P35414 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2199380 0.93 MAPK13 (0.44) MAPK13MAPK12MAPK11MAPK14RAB9A
SCHEMBL12164670 0.92 RAB9A (0.42) RAB9ANPC1SMN1; SMN2MAPTHPGD
SCHEMBL2198484 0.91 POLB (0.46) MAPK13MAPK12MAPK11MAPK14RAB9A
SCHEMBL2202440 0.90 NPC1 (0.53) MAPK13MAPK12MAPK11MAPK14RAB9A
SCHEMBL2197745 0.88 MAPK13 (0.46) MAPK13MAPK12MAPK11MAPK14RAB9A
SCHEMBL2199303 0.88 MAPK13 (0.50) MAPK13MAPK12MAPK11MAPK14RAB9A
SCHEMBL2571138 0.86 MAPT (0.49) MAPK13MAPK12MAPK11MAPK14RAB9A
SCHEMBL2198948 0.86 MAPK14 (0.42) MAPK13MAPK12MAPK11MAPK14RAB9A
SCHEMBL2197272 0.86 CD274 (0.56) SMN1; SMN2KMT2A
SCHEMBL2196670 0.86 MAPK14 (0.51) MAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP claimed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP claimed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US claimed
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 MAPK13 1063/4885MAPK12 955/4885MAPK11 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.